US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
US biotech Arvinas has promoted Ian Taylor to president of R&D. Angela Cacace will take over from Dr Taylor in his current role of chief scientific officer. 18 June 2024
US gene therapy company Regenxbio has announced that co-founder Kenneth Mills is to step down as president and chief executive following 15 years of leadership at the company. 12 June 2024
UK-based AI-driven precision medicines company Exscientia today announced the appointment of two technology and clinical development leaders to senior roles. 6 June 2024
Sapreme, a Dutch biotech developing next-generation RNA therapeutics for genetically-driven diseases, has appointed Marco Timmers as chief executive. 28 May 2024
SynaptixBio, a UK biotech that claims to be the world’s only company developing a therapy for TUBB4A-related leukodystrophies, has appointed Uwe Meya as chief medical officer (CMO). 23 May 2024
Swiss biotech Idorsia today announced changes to its executive committee (IEC) and will propose changes in membership of the board of directors at the upcoming annual general meeting of shareholders (AGM), to be held on June 13, 2024. 21 May 2024
Swiss family-owned protein specialist Octapharma has appointed pharmaceutical industry veteran Kelly Hearn as vice president of commercial development and marketing of its American company, Octapharma USA.
Ms Hearn will take immediate leadership 20 May 2024
Boston, USA-based genomic medicines company Ensoma has announced the appointment of Jim Burns as chief executive and a member of the board of directors. 13 May 2024